索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]宁小平,陆方林,徐志云,等.心房功能性二尖瓣反流研究进展[J].国际心血管病杂志,2021,05:277-280.
点击复制

心房功能性二尖瓣反流研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年05期
页码:
277-280
栏目:
综述
出版日期:
2021-10-01

文章信息/Info

Title:
-
作者:
宁小平;陆方林;徐志云;乔帆
200433 上海,海军军医大学附属长海医院心血管外科
Author(s):
-
关键词:
心房功能性二尖瓣反流;  继发性二尖瓣反流;  心房颤动;  射血分数保留性心力衰竭
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.05.006
文献标识码:
-
摘要:
心房功能性二尖瓣反流患者的左室大小和收缩功能基本正常,但常伴二尖瓣瓣环扩张以及瓣叶对合不良。射血分数保留性心力衰竭和心房颤动导致的心房功能性二尖瓣反流发病率逐年上升,其病理学机制可能与神经激素失调相关,超声心动图、核磁共振成像是影像学评估的重要方法。
Abstract:
-

参考文献/References

[1] de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development[J]. J Card Surg, 2011, 26(4):385-392.
[2] Citerni C, Kirchhoff J, Olsen LH, et al. Characterization of atrial and ventricular structural remodeling in a porcine model of atrial fibrillation induced by atrial tachypacing[J]. Front Vet Sci, 2020, 7:179.
[3] Levack MM, Jassar AS, Shang EK, et al. Three-dimensional echocardiographic analysis of mitral annular dynamics: implication for annuloplasty selection[J]. Circulation, 2012, 126(11 Suppl 1):S183-S188.
[4] Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol, 2017, 14(10):591-602.
[5] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study[J]. Circulation, 2014, 129(8):837-847.
[6] Kim DH, Heo R, Handschumacher MD, et al. Mitral valve adaptation to isolated annular dilation: insights into the mechanism of atrial functional mitral regurgitation[J]. JACC Cardiovasc Imaging, 2019, 12(4):665-677.
[7] Gertz ZM, Raina A, Saghy L, et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control[J]. J Am Coll Cardiol, 2011, 58(14):1474-1481.
[8] Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart ailure with preserved ejection fraction and atrial fibrillation: vicious twins[J]. J Am Coll Cardiol, 2016, 68(20):2217-2228.
[9] Levine RA, Hagége AA, Judge DP, et al. Mitral valve disease—morphology and mechanisms[J]. Nat Rev Cardiol, 2015, 12(12):689-710.
[10] Kagiyama N, Hayashida A, Toki M, et al. Insufficient leaflet remodeling in patients with atrial fibrillation: association with the severity of mitral regurgitation[J]. Circ Cardiovasc Imaging, 2017, 10(3):e005451.
[11] Hoit BD. Atrial functional mitral regurgitation[J]. Curr Opin Cardiol, 2020, 35(5): 474-481.
[12] Lancellotti P, Moura L, Pierard LA, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation(native valve disease)[J]. Eur J Echocardiogr, 2010, 11(4):307-332.
[13] Ring L, Dutka DP, Wells FC, et al. Mechanisms of atrial mitral regurgitation: insights using 3D transoesophageal echo[J]. Eur Heart J Cardiovasc Imaging, 2014, 15(5):500-508.
[14] Garg P, Swift AJ, Zhong L, et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging[J]. Nat Rev Cardiol, 2020, 17(5):298-312.
[15] Patel RB, Delaney JA, Hu M, et al. Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study[J]. JCI Insight, 2020, 5(19):e141656.
[16] Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation[J]. Circulation, 2019, 139(11):1354-1365.
[17] Mullens W, Martens P. Sacubitril/Valsartan to reduce secondary mitral regurgitation[J]. Circulation, 2019, 139(11):1366-1370.
[18] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395.
[19] Bartko PE, Arfsten H, Heitzinger G, et al. Papillary muscle dyssynchrony-mediated functional mitral regurgitation: mechanistic insights and modulation by cardiac resynchronization[J]. JACC Cardiovasc Imaging, 2019, 12(9):1728-1737.
[20] van der Bijl P, Vo NM, Leung M, et al. Impact of atrial fibrillation on improvement of functional mitral regurgitation in cardiac resynchronization therapy[J]. Heart Rhythm, 2018, 15(12):1816-1822.
[21] Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation[J]. N Engl J Med, 2010, 362(15):1363-1373.
[22] Zhao L, Jiang W, Zhou L, et al. The role of valvular regurgitation in catheter ablation outcomes of patients with long-standing persistent atrial fibrillation[J]. Europace, 2014, 16(6):848-854.
[23] Nishino S, Watanabe N, Ashikaga K, et al. Reverse remodeling of the mitral Valve complex after radiofrequency catheter ablation for atrial fibrillation a serial 3-dimensional echocardiographic study[J]. Circ Cardiovasc Imaging, 2019, 12(10):e009317.
[24] Itakura K, Hidaka T, Nakano Y, et al. Successful catheter ablation of persistent atrial fibrillation is associated with improvement in functional tricuspid regurgitation and right heart reverse remodeling[J]. Heart Vessels, 2020, 35(6):842-851.
[25] Packer DL, Mark DB, Robb RA, et al. Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation(CABANA)trial: study rationale and design[J]. Am Heart J, 2018, 199:192-199.
[26] Takahashi Y, Abe Y, Sasaki Y, et al. Mitral valve repair for atrial functional mitral regurgitation in patients with chronic atrial fibrillation[J]. Interact Cardiovasc Thorac Surg, 2015, 21(2):163-168.
[27] Takahashi Y, Abe Y, Takashi M, et al. Mid-term results of valve repairs for atrial functional mitral and tricuspid regurgitations[J]. Gen Thorac Cardiovasc Surg, 2019, 68(5):467-476.
[28] Matsumori M, Kawashima M, Aihara T, et al. Efficacy of left atrial plication for atrial functional mitral regurgitation[J]. Gen Thorac Cardiovasc Surg, 2020, 69(3):458-465.
[29] Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry[J]. J Am Coll Cardiol, 2014, 64(9):875-884.
[30] Arsalan M, Agricola E, Alfieri O, et al. Effect of transcatheter mitral annuloplasty with the cardioband device on 3-dimensional geometry of the mitral annulus[J]. Am J Cardiol, 2016, 118(5):744-749.
[31] Messika-Zeitoun D, Nickenig G, Latib A, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the cardioband system: 1 year outcomes[J]. Eur Heart J, 2019, 40(5):466-472.
[32] Nickenig G, Schueler R, Dager A, et al. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system[J]. J Am Coll Cardiol, 2016, 67(25):2927-2936.

备注/Memo

备注/Memo:
通信作者:乔帆,E-mail:qiaofan@smmu.edu.cn
更新日期/Last Update: 2021-10-01